Medical Research Law & Policy Report is a smart, risk-avoidance tool for entities engaged in clinical research, including hospitals, universities, contract research organizations, and...
The National Institutes of Health officially established its new center for translational research and dissolved the National Center for Research Resources, the agency announced Dec. 23, 2011.
The National Center for Advancing Translational Sciences will work to catalyze innovations in translational science, NIH stated, by working closely with partners in the regulatory, academic, nonprofit, and private sectors to identify and overcome hurdles that slow the development of effective treatments and cures. According to the frequently asked questions on the NCATS website, there is a need for the new center because it currently takes an average of 13 years and $1 billion to develop a new drug.
“Patients suffering from debilitating and life threatening diseases do not have the luxury to wait the 13 years it currently takes to translate new scientific discoveries into treatments that could save or improve the quality of their lives. The entire community must work together to forge a new paradigm, and NCATS aims to catalyze this effort,” NIH Director Francis S. Collins said in a statement.
When Collins first announced plans to create the new center more than a year ago, he said he wanted it up and running by Oct. 1, 2011, the beginning of the 2012 fiscal year (9 MRLR 786, 12/15/10; 10 MRLR 342, 5/18/11).
However, Congress did not pass an FY 2012 funding measure for NIH by Oct. 1, nor did it authorize the new center through any other legislation. NIH established the new center on the same day President Obama signed an FY 2012 appropriations bill into law (Pub. L. No. 112-74) that provides NIH with $30.7 billion in funding as well as the authorization needed to open NCATS and dissolve NCRR (10 MRLR 841, 12/21/11).
“Congressional support for the National Center for Advancing Translational Sciences marks a major milestone in mobilizing the community effort required to revolutionize the science of translation,” Collins stated.
NIH said the programs that will comprise NCATS are:
• Bridging Interventional Development Gaps, which makes available critical resources needed for the development of new therapeutic agents;
• Clinical and Translational Science Awards, which fund a national consortium of medical research institutions working together to improve the way clinical and translational research is conducted nationwide;
• Cures Acceleration Network, which enables NCATS to fund research in new and innovative ways;
• Food and Drug Administration-NIH Regulatory Science, an interagency partnership that aims to accelerate the development and use of better tools, standards, and approaches for developing and evaluating diagnostic and therapeutic products;
• Office of Rare Diseases Research, which coordinates and supports rare diseases research;
• Components of the Molecular Libraries, an initiative that provides researchers with access to the large-scale screening capacity necessary to identify compounds that can be used as chemical probes to validate new therapeutic targets; and
• Therapeutics for Rare and Neglected Diseases, a program to encourage and speed the development of new drugs for rare and neglected diseases.
The omnibus spending law provides NCATS with a budget of $575 million. NIH said the agency is funding the new center primarily by reallocating funds from programs previously located in the NIH Office of the Director, the National Human Genome Research Institute, and the National Center for Research Resources. NIH said it has maintained a “relatively stable ratio of funding” across basic and applied research and that the funding ratio will not be disturbed by the establishment of the new center.
NIH is in the process of reorganizing “a wide range of pre-clinical and clinical translational science capabilities within NIH into an integrated scientific enterprise with new leadership,” the agency said in an announcement. Acting NCATS Director Thomas R. Insel, who is the director of the National Institute of Mental Health, and acting NIH Deputy Director Kathy Hudson will lead the reorganization effort. NIH said it is continuing to recruit a permanent director for NCATS.
More information on NCATS is available at http://www.nih.gov/about/director/ncats/index.htm .
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)